ASCO GU 2022: Real-World Experience of Axitinib As Second-Line Treatment in Metastatic Renal Cell Carcinoma: Analysis of the Swedish Population

(UroToday.com) The Poster Session C on the third day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022 focused on Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers. In this session, Dr. Strambi presented a real-world experience from Sweden examining the outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with second-line axitinib.

Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3 that was approved in 2012 for the treatment of metastatic renal cell carcinoma (mRCC) after the failure of prior treatment with sunitinib or a cytokine. While clinical trials are critical for registration, Dr. Strambi highlighted that it is important to describe the clinical outcomes of more heterogeneous, real-world populations. Thus, in this analysis, the authors described the time-to-treatment discontinuation (TTD) and overall survival (OS) among patients receiving second-line axitinib in a real-world setting using a nationwide Swedish mRCC cohort.

The authors used the Swedish Health Data Registers, covering the entire Swedish population to perform retrospective analysis. The authors identified adult patients (aged ≥ 18 years) with mRCC who had ≥ 1 filled prescription of axitinib in the second-line setting, after an anti-angiogenic targeted therapy, from marketing approval until December 2019. This analysis relied on data relating to dispensed pack size, strength, and dosing as recommended by the product label. A grace period of 90 days was allowed between filled prescriptions including medication accumulated from overlapping prescriptions. The Kaplan-Meier technique was used to describe TTD and OS.

The authors identified 110 patients who received second-line axitinib in Sweden during the study period. Patients were predominantly male (n = 84, 76.4%) with a mean (SD) age of 60.9 (9.6) years at diagnosis and 65.5 (9.9) years at the initiation of second-line therapy. The median time to TTD was 5.2 (95% CI 3.7-6.1) months, with 6 (5.5%) patients still receiving treatment at the time of analysis. The median OS was 12.2 (95% CI 7.7 -14.2) months with 25.5% (n = 28) of patients censored at the time of analysis.

ASCO GU 2022_Strambi _0 

Thus, the authors conclude that this real-world analysis of the Swedish population demonstrated the results with second-line axitinib in mRCC was generally consistent with published randomized controlled trials.

Presented by: Angela Strambi, Ph.D., Medical Affairs, Pfizer AB, Stockholm, Sweden

 

Written by: Christopher J.D. Wallis, University of Toronto Twitter: @WallisCJD during the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, Thursday Feb 17 – Saturday Feb 19, 2022

 
 
email news signup